Tech Transfer eNews Blog

EpiVario enters option agreement with U Penn to advance potential Alzheimer’s treatments


By Jesse Schwartz
Published: January 13th, 2021

Preclinical drug company EpiVario has entered into an option agreement with the University of Pennsylvania (Penn) to advance potential treatments for early-stage Alzheimer’s disease.

The option is centered on Penn research that shows how certain epigenomic changes impact Alzheimer’s disease pathways by disrupting feedback loops between genes and chromatin. These changes drive the disease, altering gene expression by marking proteins known as histones that package and protect DNA.

According to Penn researchers, the activity of these epigenetic regulators could be inhibited by therapeutics. Through the option agreement, EpiVario will seek to identify modulators that could potentially limit epigenetic regulator activity to prevent Alzheimer’s disease.

“Given the incidence of Alzheimer’s disease around the world and its devastating effects on individuals, there has never been a greater need for early intervention,” says Shelley Berger, professor at Penn and senior scientist on the research. “With this new epigenetic marker, there is an opportunity to develop novel therapeutics that can inhibit the epigenetic regulators that contribute to the disease.”

In addition to the option agreement, EpiVario has closed its $717,000 seed funding round and plans to use the funds to advance its addiction therapy research and explore endeavors in the realm of memory-related disorders.

“Our mission is to develop new therapeutics that will ease the burden of memory-related diseases, such as PTSD and now Alzheimer’s, which can be fatal to patients and present an extreme burden to their family, friends, and society as a whole,” says Thomas Kim, CEO of EpiVario. “We are thrilled to continue our collaboration with the University of Pennsylvania, as well as to close this round of funding to help us continue and expand our research around the development of effective therapeutics for PTSD, addiction therapy, and other memory-related disorders such as Alzheimer’s.”

Source: Cision

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment